An article titled “How a New Action Plan is Putting the Baltics on the Biotech Map” published in Drug Discovery World (DDW). Written by Bruno Quinney and Diana Turner, it examines the growing biotech market in the Baltics.
Combining cutting-edge science with agile policy, Lithuania, Latvia, and Estonia are coming together to create the Baltic Biotech Hub.
Since regaining independence in 1990, the countries have made significant economic progress, with biotechnology emerging as a priority for all three. However, leaders recognized that a comprehensive regional biotechnology ecosystem would provide the capacity to reach a ‘critical mass’ that is unavailable locally. The Baltic Biotech Action Plan, a strategic initiative of the ‘BioConnect’ project, aims to facilitate this. The initiative identifies the key challenges of such an ecosystem and proposes effective solutions to overcome them with the right mix of talent, infrastructure, funding, and political support.
Each nation within the Baltics offers unique specialist knowledge in different areas of biotechnology. As Agnė Vaitkevičienė, Vice-President of LithuaniaBIO, explains in an interview with DDW: “Each of the three countries has very different strengths. For instance, Estonia is very strong in digital health, biobanking, and creating health data solutions. Latvia has a very long history of organic synthesis and pharmaceuticals, particularly on the generic side. In Lithuania, there’s a lot of R&D, gene editing, and protein synthesis – resulting in lots of biotechnology success stories.”
Lithuania is a regional leader in biotechnology, and its investment landscape has been strong in recent years. As part of this trend, multi-omics data analysis company VUGENE raised €1 million in 2025 from the Finnish venture capital firm Superhero Capital with participation of NGL Ventures, Coinvest Capital, and angel investors.
VUGENE democratizes access to powerful multi-omics analysis through a customizable, scalable AI/ML platform. It accelerates therapeutic R&D by combining deep biological insights with scientific expertise and human intelligence – turning large, raw datasets into informed and actionable R&D decisions.
Read full article: Link
Published by: Drug Discovery World (DDW) on February 26, 2026
Cover photo credits: Omar
